Comparison of Histamine 2 Receptor Antagonists and Proton Pump Inhibitors on Infectious Complications in Critically Ill Patients

Sun-young PARK; Jae-Hee CHOI; Young-Ju YOUN; Sandy-Jeong RHIE.
Korean Journal of Clinical Pharmacy ; : 46-52, 2016.
Artículo en Ko | WPRIM | ID: wpr-62950

Documentos relacionados

  1. An Updated View on the Cellular Uptake and Mode-of-Action of Clostridioides difficile Toxins.
  2. [Gastro-intestinal infections with Clostridium difficile in the elderly].
  3. The glucosyltransferase activity of C. difficile Toxin B is required for disease pathogenesis.
  4. Follow-on rifaximin for the prevention of recurrence following standard treatment of infection with <i>Clostridium difficile</i>: a competing risks analysis provides a full picture of possible treatment effects.
  5. Colonization With Toxicogenic C. difficile Upon Hospital Admission.
  6. Response to Matuchansky. [corrected].
  7. Bezlotoxumab - A New Agent for Clostridium difficile Infection.
  8. Bezlotoxumab and Recurrent Clostridium difficile Infection.
  9. Bezlotoxumab and Recurrent Clostridium difficile Infection.
  10. Bezlotoxumab and Recurrent Clostridium difficile Infection.